Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
-
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
-
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
-
Plus Therapeutics Announces New Employment Inducement Grants
-
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
-
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
-
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
-
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
-
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
-
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense